-
Aug 12, 2024 | 
evidencebaseonline.com | Phillip C. Garner
Healthcare is inconsistent across the US. Factors such as a patient’s financial situation, insurance plan, access to care and physical location create disparities that affect health outcomes and costs. Once often considered irrelevant, social determinants of health (SDOH) data is having a significant influence on health economics and outcomes research (HEOR).
-
Jul 3, 2024 | 
evidencebaseonline.com | Phillip C. Garner
Novel real-world endpoints derived from real-world data (RWD) offer a promising avenue for enhancing the regulatory decision-making process. By capturing data on patient outcomes, treatment patterns and real-world effectiveness in diverse clinical settings, these endpoints also support a broader shift towards a more patient-centered approach in drug development and regulation.
-
Jul 1, 2024 | 
evidencebaseonline.com | Joanne Walker |Phillip C. Garner
Etranacogene dezaparvovec (HEMGENIX®) is the first and currently only gene therapy approved for hemophilia B in the UK and is made available under the Innovative Medicines Fund. As the National Institute for Health and Care Excellence (NICE) and the NHS grapple with the high upfront costs and uncertainty surrounding the long-term outcomes of novel cell and gene therapies in the UK, novel payment methods are being explored.
-
Jun 17, 2024 | 
evidencebaseonline.com | Phillip C. Garner
Maximizing data completeness and accuracy in real-world evidence (RWE) research is essential to ensure that research findings are valid, reliable, and reproducible. With fit-for-purpose data, stakeholders can draw greater insights, advance medical innovation, enhance regulatory processes, and make better informed decisions to improve patient outcomes.
-
Jun 14, 2024 | 
evidencebaseonline.com | Phillip C. Garner
After a challenging period for the industry, driven by macroeconomic factors and resulting in a significant downturn, are we seeing green shoots to give us some optimism? In this article, the latest instalment of the Talent Hub, Martin Anderson (Founding Director, Carrot Recruitment) looks at this from the point-of-view of market sentiment.
-
Jun 10, 2024 | 
evidencebaseonline.com | Phillip C. Garner
In the rapidly evolving landscape of health technology assessment (HTA), decision-makers are looking to real-world data (RWD) to generate real-world evidence (RWE) on the effectiveness, safety, and cost-effectiveness of health technologies. Methodologies, such as target trial emulation (TTE), have emerged to address challenges such as confounding and selection bias that often afflict observational studies to enable causal inferences to be made.
-
Jun 5, 2024 | 
evidencebaseonline.com | Phillip C. Garner
Disparities in health outcomes and access to health care among different population groups are becoming increasingly important to be considered in health technology assessment (HTA) and reimbursement decision-making. To ensure that health inequalities are appropriately and systematically considered by all stakeholders, there is a need for a clear framework, better methods to measure inequality, and a shared understanding of how these factors should be considered alongside clinical outcomes.
-
Jun 5, 2024 | 
evidencebaseonline.com | Phillip C. Garner
Since the establishment of the UK’s National Institute for Clinical Excellence (NICE) in 1999, which aimed to evaluate the clinical and cost effectiveness of new healthcare innovations, life science companies have been required to participate in various health technology and value assessments.
-
May 30, 2024 | 
evidencebaseonline.com | Phillip C. Garner
“Caring about health is a luxury” If you’re like me, maybe you quickly read over this statement and thought, “yes, of course,” and then moved on to the next paragraph. But let's take a moment to reconsider it: “Caring about health is a luxury.” Pause and envision a real person or a population who may not have the luxury to care about their health. It gives the sentence a whole new perspective, doesn’t it?
-
May 29, 2024 | 
evidencebaseonline.com | Katie McCool |Phillip C. Garner
IDERHA’s report examines global real-world data (RWD) and real-world evidence (RWE) policies, highlighting advancements and challenges, aiming to foster coherence and transparency in evidence-based health care. The use of RWE has become increasingly important for informing decisions in health care.
